NCT02046564已完成3 期
A Multicenter, Randomized, Double-blind Trial to Assess the Efficacy and Safety of ASC-01 in Patients With Major Depressive Disorder
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 412
- 主要终点
- The Mean Change From Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score
研究概览
简要总结
To evaluate the efficacy and the safety of ASC-01 (aripiprazole/sertraline combination) compared to sertraline monotherapy in patients with major depressive disorders who have responded incompletely to sertraline monotherapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 20 Years 至 64 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who are either inpatients or outpatients.
- •Patients who are able to understand necessary information for giving consent to undergo examinations, observations, and evaluations specified in this clinical protocol, and who are able to give written consent based on a full understanding of the trial.
- •Patients who have been given a diagnosis of "Major Depressive Disorder, Single Episode" or "Major Depressive Disorder, Recurrent" according to the DSM-5 and who have a current episode of major depression that has been continuing for at least 8 weeks
- •Patients with a HAM-D 17 total score of 18 or more at the Screening Period evaluation
排除标准
- •Female patients of childbearing potential who wish to become pregnant during the trial period or within 4 weeks after completion or discontinuation of the trial
- •Pregnant or breast-feeding female patients, or female patients who may be pregnant
- •Patients judged to be intolerant to all antidepressant (including drugs not used for their current episodes of major depression) based on their treatment history
- •Patients who have had electroconvulsive therapy
- •Patients who have enrolled in a clinical trial of other drugs or medical devices within 1 month before the time of informed consent
- •Patients who have a medical history suggesting a risk of developing serious adverse events or symptoms that may hinder efficacy/safety evaluation (eg, symptoms of fibromyalgia, or premenstrual syndrome etc that overlap with depressive symptoms)
- •Patients with complications or a history of diabetes mellitus, or patients who have been judged to be diabetic
- •fasting blood glucose level ≥ 126 mg/dL
- •2-hour glucose level in 75-g oral glucose tolerance test (OGTT) ≥ 200 mg/dL
- •non-fasting blood glucose level ≥ 200 mg/dL
- •HbA1c [NGSP level] ≥ 6.5%
- •Patients who are undergoing treatment for thyroid disease (except for patients whose disease has been stabilized with drug therapy for 3 months or longer before the time of informed consent)
- •Patients who have a history of neuroleptic malignant syndrome or serotonin syndrome
- •Patients who have a history of seizure disorder (eg, epilepsy)
研究组 & 干预措施
ASC-01
Experimental
The dose of 3-12mg/100mg(Aripiprazole/Sertraline Combination)will be orally administered once daily
干预措施: ASC-01 (Drug)
Placebo
Placebo Comparator
The dose of 0mg/100mg (Placebo/Sertraline Combination ）will be orally administered once daily
干预措施: Placebo (Drug)
结局指标
主要结局
The Mean Change From Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score
时间窗: 8 weeks after the start of the sertraline treatment period (Baseline), 6 weeks after the start of the double-blind period (Last Observation Carried Forward [LOCF])
The MADRS is a clinician-rated scale which evaluates the level of depression. The MADRS consists of 10 items assessing apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, suicidal thought. Each item is scored from 0 to 6, with higher scores indicating worse condition.Summed subscales are combined to compute a total score. Total score ranges from 0 to 60, with higher score indicating worse condition.
次要结局
- The Montgomery-Åsberg Depression Rating Scale (MADRS) Response Rate(8 weeks after the start of the sertraline treatment period (Baseline), 6 weeks after the start of the double-blind period (Last Observation Carried Forward [LOCF]))
- The Mean Change From Baseline in the Clinical Global Impression - Severity of Illness (CGI-S)(8 weeks after the start of the sertraline treatment period (Baseline), 6 weeks after the start of the double-blind period (Last Observation Carried Forward [LOCF]))
- The Mean Change From Baseline in the Apathy Scale (AS) Total Score(8 weeks after the start of the sertraline treatment period (Baseline), 6 weeks after the start of the double-blind period (Last Observation Carried Forward [LOCF]))
- The Montgomery-Åsberg Depression Rating Scale (MADRS) Remission Rate(8 weeks after the start of the sertraline treatment period (Baseline), 6 weeks after the start of the double-blind period (Last Observation Carried Forward [LOCF]))
- The Clinical Global Impression - Improvement (CGI-I) Improvement Rate(6 weeks after the start of the double-blind period (Last Observation Carried Forward [LOCF]))
- The Mean Change From Baseline in the Hamilton Depression Rating Scale 17 (HAM-D17) Total Score(8 weeks after the start of the sertraline treatment period (Baseline), 6 weeks after the start of the double-blind period (Last Observation Carried Forward [LOCF]))
- The Mean Change From Baseline in the Social Adaptation Self-evaluation Scale (SASS) Total Score(8 weeks after the start of the sertraline treatment period (Baseline), 6 weeks after the start of the double-blind period (Last Observation Carried Forward [LOCF]))
- The Mean Change From Baseline in the Self-rating Version of Montgomery-Åsberg Depression Rating Scale (MADRS-S) Total Score(8 weeks after the start of the sertraline treatment period (Baseline), 6 weeks after the start of the double-blind period (Last Observation Carried Forward [LOCF]))
研究者
相似试验
已完成
1 期
Bioequivalence Between Single Administration of ASC-01 (Aripiprazole/Sertraline Combination Drug) and Concomitant Single Administration of Aripiprazole and Sertraline, and Food Effect on Pharmacokinetics of ASC-01 in Healthy Male AdultsJPRN-jRCT2080223718Otsuka Pharmaceutical Co., Ltd.74
进行中（未招募）
3 期
Clinical and cost-effectiveness of an aripiprazole and sertraline drug combination in comparison with the drug quetiapine for the treatment of bipolar depressioBipolar depressionMental and Behavioural DisordersISRCTN63917405Cumbria Northumberland Tyne and Wear NHS Foundation Trust270
已完成
1 期
Bioequivalence Between Single Administration of ASC-01 (Aripiprazole/Sertraline Combination Drug) and Concomitant Single Administration of Aripiprazole and Sertraline, and Food Effect on Pharmacokinetics of ASC-01 in Healthy Male AdultsHealthy Male AdultsNCT03342963Otsuka Pharmaceutical Co., Ltd.74
已完成
3 期
Aliskiren and the Calcium Channel Blocker Amlodipine Combination as an Initial Treatment Strategy for HypertensionHypertensionNCT00797862Novartis1,254
已完成
3 期
Study of Aripiprazole in Patients With Acute Bipolar ManiaBipolar DisorderNCT00097266Otsuka Pharmaceutical Development & Commercialization, Inc.615